Revance Therapeutics (RVNC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2013 | 03-2013 | 12-2012 | 12-2011 | |
| Cash Flows From Operating Activities | ||||
| Net Income | -33,486 | -21,657 | -58,250 | -44,860 |
| Depreciation Amortization | 3,895 | 3,375 | 9,500 | 7,110 |
| Accounts payable and accrued liabilities | 5,187 | 1,854 | N/A | N/A |
| Other Working Capital | -6,405 | 3,107 | -7,120 | -60 |
| Other Operating Activity | 3,503 | 6,738 | 16,960 | 9,400 |
| Operating Cash Flow | $-27,306 | $-6,583 | $-38,910 | $-28,410 |
| Cash Flows From Investing Activities | ||||
| PPE Investments | -2,318 | -325 | -310 | -150 |
| Other Investing Activity | 75 | 75 | 70 | 80 |
| Investing Cash Flow | $-2,243 | $-250 | $-240 | $-70 |
| Cash Flows From Financing Activities | ||||
| Debt Repayment | -4,318 | -2,124 | N/A | N/A |
| Common Stock Issued | 7 | 1 | N/A | N/A |
| Other Financing Activity | 40,703 | 31,782 | 13,620 | 54,060 |
| Financing Cash Flow | $36,392 | $29,659 | $13,620 | $54,060 |
| Beginning Cash Position | 4,083 | 4,083 | 29,620 | 4,040 |
| End Cash Position | 10,926 | 26,909 | 4,080 | 29,620 |
| Net Cash Flow | $6,843 | $22,826 | $-25,530 | $25,570 |
| Free Cash Flow | ||||
| Operating Cash Flow | -27,306 | -6,583 | -38,910 | -28,410 |
| Capital Expenditure | -2,318 | -325 | N/A | N/A |
| Free Cash Flow | -29,624 | -6,908 | -38,910 | -28,410 |